MOH Stock Analysis: Molina Healthcare | NYSE
Healthcare Plans | NYSE, USA | Market Cap: 9.440m USD | 12M Return: -3.3% | US60855R1005 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 116M
EPS Trend: -72.2%
Qual. Beats: 0
Rev. Trend: 96.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Molina Healthcare, Inc. is a managed care company that delivers healthcare services primarily to low-income families and individuals across the United States. Its operations are organized into four segments: Medicaid, Medicare, Marketplace, and Other. The company is headquartered in Long Beach, California, and was founded in 1980.
As a managed health care provider, Molina operates under contracts with government programs and insurance marketplaces, receiving fixed payments per member in exchange for delivering or arranging medical services. Its core focus on Medicaid aligns it with the joint federal-state program that serves low-income and disabled populations, while its Medicare segment addresses federally administered coverage for seniors and certain disabled individuals. The Marketplace segment reflects participation in the Affordable Care Act exchanges.
- Medicaid redeterminations pressure membership and medical loss ratios
- Medicare Advantage margins hinge on star ratings and bonus payments
- Marketplace enrollment grows on extended enhanced ACA subsidies
- State contract wins and acquisitions expand Medicaid footprint
| Net Income: -7.00m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.94 > 1.0 |
| NWC/Revenue: 11.74% < 20% (prev 12.06%; Δ -0.32% < -1%) |
| CFO/TA 0.02 > 3% & CFO 365.0m > Net Income -7.00m |
| Net Debt (-4.78b) to EBITDA (371.0m): -12.88 < 3 |
| Current Ratio: 1.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.3m) vs 12m ago -5.52% < -2% |
| Gross Margin: 12.22% > 18% (prev 10.94%; Δ 1.28% > 0.5%) |
| Asset Turnover: 276.4% > 50% (prev 267.8%; Δ 8.60% > 0%) |
| Interest Coverage Ratio: 0.97 > 6 (EBIT TTM 203.0m / Interest Expense TTM 209.0m) |
| A: 0.33 (Total Current Assets 12.9b - Total Current Liabilities 7.70b) / Total Assets 16.0b |
| B: 0.23 (Retained Earnings 3.68b / Total Assets 16.0b) |
| C: 0.01 (EBIT TTM 203.0m / Avg Total Assets 16.1b) |
| D: 0.35 (Book Value of Equity 4.17b / Total Liabilities 11.8b) |
| Altman-Z'' = 3.35 = A |
| DSRI: 0.88 (Receivables 3.48b/3.87b, Revenue 44.5b/43.4b) |
| GMI: 0.89 (GM 10.94% / 12.22%) |
| AQI: 1.00 (AQ_t 0.17 / AQ_t-1 0.17) |
| SGI: 1.03 (Revenue 44.5b / 43.4b) |
| TATA: -0.02 (NI -7.00m - CFO 365.0m) / TA 16.0b) |
| Beneish M = -3.20 (Cap -4..+1) = AA |
As of October 06, 2026, the stock is trading at USD 194.05 with a total of 903,653 shares traded. Over the past week, the price has changed by +2.33%, over one month by -1.15%, over three months by -14.78% and over the past year by -3.25%.
Current recommended Stop Loss: 185.20 (which is 4.6% or 1.2 ATR below the current price).
Molina Healthcare has received a consensus analysts rating of 3.32. Therefore, it is recommended to hold MOH.
- StrongBuy: 3
- Buy: 1
- Hold: 14
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 209.1 | 7.8% |
P/E Trailing = 1291.7858
P/E Forward = 18.9036
P/S = 0.2223
P/B = 2.3927
P/EG = 0.887
Revenue TTM = 44.5b USD
EBIT TTM = 203.0m USD
EBITDA TTM = 371.0m USD
Long Term Debt = 3.77b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 4.14b USD (from shortLongTermDebtTotal, last quarter) + Leases 184.0m
Net Debt = -4.78b USD (calculated: Debt 4.14b - CCE 8.91b)
Enterprise Value = 4.66b USD (9.44b + Debt 4.14b - CCE 8.91b)
Interest Coverage Ratio = 0.97 (Ebit TTM 203.0m / Interest Expense TTM 209.0m)
EV/FCF = 17.20x (Enterprise Value 4.66b / FCF TTM 271.0m)
FCF Yield = 5.81% (FCF TTM 271.0m / Enterprise Value 4.66b)
FCF Margin = 0.61% (FCF TTM 271.0m / Revenue TTM 44.5b)
Net Margin = -0.02% (Net Income TTM -7.00m / Revenue TTM 44.5b)
Gross Margin = 12.22% ((Revenue TTM 44.5b - Cost of Revenue TTM 39.1b) / Revenue TTM)
Gross Margin QoQ = 8.54% (prev 9.47%)
Tobins Q-Ratio = 0.29 (Enterprise Value 4.66b / Total Assets 16.0b)
Interest Expense / Debt = 5.05% (Interest Expense 209.0m / Debt 4.14b)
Taxrate = 34.07% (31.0m / 91.0m)
NOPAT = 133.8m (EBIT 203.0m * (1 - 34.07%))
Current Ratio = 1.68 (Total Current Assets 12.9b / Total Current Liabilities 7.70b)
Debt / Equity = 0.99 (Debt 4.14b / totalStockholderEquity, last quarter 4.17b)
Debt / EBITDA = -12.88 (Net Debt -4.78b / EBITDA 371.0m)
Debt / FCF = -17.63 (Net Debt -4.78b / FCF TTM 271.0m)
Total Stockholder Equity = 4.13b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.04% (Net Income -7.00m / Total Assets 16.0b)
RoE = -0.17% (Net Income TTM -7.00m / Total Stockholder Equity 4.13b)
RoCE = 2.57% (EBIT 203.0m / Capital Employed (Equity 4.13b + L.T.Debt 3.77b))
RoIC = 2.20% (NOPAT 133.8m / Invested Capital 6.08b)
WACC = 4.76% (E(9.44b)/V(13.6b) * Re(5.39%) + D(4.14b)/V(13.6b) * Rd(5.05%) * (1-Tc(0.34)))
Discount Rate = 5.39% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.94 | Cagr: -5.53%
[DCF] Terminal Value 73.10% ; FCFF base≈333.4m ; Y1≈292.4m ; Y5≈236.2m
[DCF] Fair Price = 164.2 (EV 3.79b - Net Debt -4.78b = Equity 8.57b / Shares 52.2m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -72.17 | EPS CAGR: -40.04% | SUE: 0.11 | # QB: 0
Revenue Correlation: 96.40 | Revenue CAGR: 12.78% | SUE: 0.37 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.79 | Chg30d=-4.29% | Revisions=-65% | Analysts=18
EPS current Year (2026-12-31): EPS=5.25 | Chg30d=+0.15% | Revisions=+35% | GrowthEPS=-52.4% | GrowthRev=-2.1%
EPS next Year (2027-12-31): EPS=8.55 | Chg30d=+0.00% | Revisions=+22% | GrowthEPS=+190.1% | GrowthRev=+8.1%
[Analyst] Revisions Ratio: -9% (up=18, down=22)